Reference
- Frucht-Pery J, Pe' er J. Use of mitomycin C in the treatment of conjunctival primary acquired melanosis with atypia. Arch Ophthalmol. 1996;114:1261–1264.
- Finger PT, Milner MS, McCormick SA. Topical chemother-apy for conjunctival melanoma. Brit J Ophthalmol. 1993; 77:751–753.
- Finger PT, Czechonska G, Liarikos S. Topical mitomycin C chemotherapy for conjunctival melanoma and PAM with atypia. Brit J Ophthalmol. 1998;82:476–479.
- Loffler KU. Mitomycin as local therapeutic drug in ocular neoplasms. Ophthalmologe. 1997;94:529–531.
- Werschnik C, Lommatzsch PK. Mitomycin C in treatment of conjunctival melanoma and primary acquired melanosis. Klin Monatsblatt Augenheil. 1998;212:465–468.
- Nadjari B, Motherby H, Pooschke T et al. Cytologic and DMA cytometric diagnosis and therapy monitoring of squamous cell carcinoma in situ and malignant melanoma of the cornea and conjunctiva. Anal Quant Cytology and Histology. 1999;21:387–396.
- Salomao DR, Mathers WD, Sutphin JE, Cuevas K, Folberg R. Cytologic changes in the conjunctiva mimicking malig-nancy after topical mitomycin C chemotherapy. Ophthal-mology. 1999;106:1756–1760.
- Nuyts RM MA, Felten PC, Pets E, Langerhorst CT, Geijssen HC, Grossniklaus HE, Greve EL. Histopathologic effects of mitomycin C after trabeculectomy in human glaucoma-tous eyes with persistent hypotony. Am J Ophthalmol. 1994;118:225–237.
- Gupta S, Basti S. Corneoscleral, ciliary body, and vitreo-retinal toxicity after excessive instillation of mitomycin C. (Letter). Am J Ophthalmol. 1992;114:503–504.
- Ewing-Chow DA, Romanchuk KG, Gilmour GR, Underhill JH, Climenhaga DB. Corneal melting after ptery-gium removal followed by topical mitomycin C therapy. Can J Ophthalmol. 1992;27:197–199.
- Dunn JP, Seamone CD, Ostler HB, Nickel BL, Beallo A. Development of scleral ulceration and calcification after pterygium excision and mitomycin therapy. Am J Ophthal-mol. 1991;112:343–344.
- Rubinfeld RS, Pfister RR, Stein RM, Foster CS, Martin NF, Stoleru S, Talley AR, Speaker MD. Serious complications of topical mitomycin C after pterygium surgery. Ophthal-mology. 1992;99 :1647–1654.
- Siegel D, Beall H, Senekowitsch C, Kasai M, Arai H, Gibson NW, Ross D. Bioreductive activation of mitomycin C by DT-diaphorase. Biochemistry. 1992;31:7879–7885.
- Ross D, Siegel D, Beall H, Mulcahy RT, Prakash AS, Gibson NW. Activation and detoxification of quinones by DT-diaphorase. Bioreductive activation of mitomycin C. Cancer Metastasis Reviews. 1993;12:83–101.
- Mikami K, Naito M, Tomida A, Yamada M, Sirakusa T, Tsuruo T. DT-diaphorase as a critical determinant of sensi-tivity to mitomycin C in human colon and gastric carcinoma cell lines. Cancer Res. 1996;56:2823–2826.
- Winski SL, Hargreaves RH, Butler J, Ross D. A new screening system for NAD(P)H:quinone oxidoreductase (NQ01)-directed antitumor quinones: Identification of a new aziridinylbenzoquinone, RH1, as a NQ01-directed antitumor agent. Clin Cancer Res. 1998;4:3083–3088.
- Siegel D, Franklin WA, Ross D. Immunohistochemical detection of NAD(P)H:quinone oxidoreductase in human lung and lung tumors. Clin Cancer Res. 1998;4: 2065–2070.
- Schelonka LP, Siegel D, Wilson MW, Meininger A, Ross D. Immunohistochemical localization of NQ01 in epithelial dysplasia and neoplasia and donor eyes. Invest Ophthalmol Vis Sci. 2000;41: 1617–1622.
- Traver RD, Siegel D, Beall HD et al. Characterization of a polymorphism in NAD(P)H:quinone oxidoreductase (DT-diaphorase). Br J Cancer 1997;75:69–75.
- Schlager JJ, Powis G. Cytosolic NAD(P)H:quinone accep-tor oxidoreductase in human normal and tumor tissues. Effects of cigarette smoking and alcohol. Int J Cancer 1990;45 :403–409.
- Mann A, Lopez de Cerain A, Hamilton E, Lewis AD, Martinez-Penuel JM, Idoate MA, Bello J. DT-diaphorase and cytochrome B5 reductase in human lung and breast tumours. Brit J Cancer 1997;76: 923–929.
- Beyer RE, Segura-Aguilar J, Di Bernardo S, Cavazzoni M, Fato R, Fiorentini D, Galli M, Setti M, Landi L, Lenaz G. The role of DT-diaphorase in the maintenance of the reduced antioxidant form of coenzyme Q in membrane systems. Proc Natl Acad Sci USA. 1996;93:2528–2532.
- Siegel D, Bolton EM, Burr JA, Liebler DC, Ross D. The reduction of a-tocopherolquinone by Human NAD(P)H:quinone oxidoreductase: The role of a-tocopherolhydroquinone as a cellular antioxidant. Mol PharmacoL 1997;52:300–305.
- Smit NP, Hoogduijn MJ, Riley PA, Pavel S. Study of DT-diaphorase in pigment producing cells. Cell Mol Biol. 1999;45:1041–1046.
- Wang X, Doherty GP, Leith MK et al. Enhanced cytotoxi-city of mitomycin C in human tumor cells with inducers of DT-diaphorase. Br J Cancer 1999;80 :1223–1230.
- Fitzsimmons SA, Workman P, Greyer M, Paull K, Camalier R, Lewis AD. Reductase enzyme expression across the National Cancer Institutes tumor cell line panel: Correla-tion with sensitivity to mitomycin C and E09. J Natl Cancer Inst. 1996;83:259–269.
- Malkinson AM, Siegel D, Forrest GL, Gazdar AF, Oie HK, Chan DC, Bunn PA, Mabry M, Dykes DJ, Harridan Jr. SD, Ross D. Elevated DT-diaphorase activity and mRNA content in human non-small cell lung carcinoma. Relation-ship to the response of lung tumor xenografts to mitomycin C. Cancer Res. 1992;52:4752–4757.
- Gustafson DL, Beall HD, Bolton EM, Ross D, Waldren CA. Expression of human NAD(P)H:quinone oxidoreductase (DT-diaphorase) in Chinese hamster ovary cells: Effect on the toxicity of antitumor quinones. Mol PharmacoL 1996;50:728–735.